#Warsaw #Poland #ExploRNA Therapeutics #Łukasiewicz IChP #mRNA Capping

Partnership Aim at Advanced mRNA Technologies

ExploRNA Therapeutics, a pioneering biotechnology company focused on innovative mRNA capping technologies, has announced a strategic partnership with the Łukasiewicz Research Network - Industrial Chemistry Institute (Łukasiewicz - IChP). This collaboration aims to advance the manufacturing of high-quality mRNA cap analogs, particularly leveraging their cutting-edge AvantCap Q1 technology in accordance with Good Manufacturing Practices (GMP). This initiative is critical for ensuring a stable supply of essential materials needed for mRNA therapies and vaccines currently under clinical development.

As mRNA technology continues to reshape the biopharmaceutical landscape, the demand for high-quality and scalable components is escalating rapidly. The co-transcriptional capping process is a vital step in the mRNA synthesis, significantly influencing the yield, quality, and effectiveness of the final pharmaceutical product. By partnering with Łukasiewicz - IChP, recognized for its advanced capabilities in chemical synthesis and scalable production, ExploRNA guarantees its industrial partners access to superior quality cap analogs necessary for advancing their clinical programs and commercial pipelines.

Prof. Jacek Jemielity, CEO of ExploRNA Therapeutics, emphasized the importance of this partnership: "This collaboration marks a decisive step in our growth journey. Finding a reliable and high-quality manufacturing partner that adheres to Good Manufacturing Practices is a significant milestone for ExploRNA. This partnership not only confirms the scalability of our synthesis processes but also ensures that our exclusive innovations can seamlessly transition from laboratory to life-saving clinical applications."

The production of GMP-compliant materials is essential for the ongoing development of ExploRNA's business strategy, enabling the company to support global developers in the biotechnology and pharmaceutical sectors from early research stages to advanced clinical trials and large-scale commercialization.

About ExploRNA Therapeutics

ExploRNA Therapeutics specializes in developing cutting-edge mRNA capping technologies and platform solutions. By innovating at the heart of mRNA design, the company offers solutions that significantly enhance mRNA translation efficiency for next-generation genetic medicines.

About Łukasiewicz - IChP

The Łukasiewicz Research Network - Industrial Chemistry Institute is a leading Polish research and development center specializing in chemical synthesis, process engineering, and scaling up production for the advanced pharmaceutical and chemical industries. Through this partnership, both organizations aim to bridge the gap between innovative research and practical applications in the field of biotechnology, ensuring that advancements in science translate into viable medical solutions. Their collaboration also underscores the importance of adhering to rigorous manufacturing standards to safeguard public health and accelerate the availability of life-saving therapies.